N@N

Cardiovascular Devices from Medtronic Featured Prominently at EuroPCR

^{Published on 2010-05-20 11:40:28 - Market Wire}
 

MINNEAPOLIS--([ BUSINESS WIRE ])--Medtronic, Inc. (NYSE: MDT), announced today the schedule of important clinical data presentations during EuroPCR, a major cardiology meeting taking place May 25a"28 in Paris at the Palais de Congrs.

"Continuous sinusoid technology a" the future of Medtronica™s stent pipeline"

The meeting will prominently feature several of Medtronica™s innovative cardiovascular devices, including the Resolute coronary drug-eluting stent, the IN.PACT line of coronary and peripheral drug-eluting balloons, and the CoreValve transcatheter aortic valve replacement system.

aMedtronic is the only company with technological and therapeutic expertise in coronary and peripheral interventions as well as cardiac and vascular surgery,a said Scott Ward, senior vice president of Medtronic and president of the companya™s CardioVascular business. aThe breadth and depth of our product portfolio and pipeline for these specialties is unmatched. We are uniquely positioned to work together with medical professionals across disciplines and around the world to advance the treatment of cardiovascular disease.a

EuroPCR 2010 is the first major medical meeting for interventional cardiologists and other interventionalists since Medtronic completed its acquisition of Invatec on April 21. The program includes several presentations on the novel devices developed by Invatec for the treatment of coronary and peripheral vascular disease a" most notably, the IN.PACT Admiral, Amphirion and Falcon drug-eluting balloons, and the Mo.Ma proximal embolic protection system.

Highlights of the EuroPCR program for cardiovascular devices from Medtronic follow:

[NOTE: All Central Europe Summer Time (Paris) and congress center locations.]

EuroPCR 2010 / Paris

Tuesday, May 25 (Day 1)

• The Great Debate a" Transcatheter aortic valve implantation (TAVI):
  from concept to evidence-driven practice
  12:20 a" 2:20 pm (Main Arena)
  (supported with an unrestricted educational grant from Medtronic)
• Hotline 2 a" Endovascular late breaking trials
  1:30 a" 2:20 pm (Theatre Havane)
  Starts with two presentations of clinical data on the Mo.Ma proximal embolic protection system: aArmour trial a" Final resultsa and aProximal endovascular clamping for carotid artery stenting: 1-year follow-up of a prospective registry of 1,300 consecutive patientsa
• Hotline 3 a" TAVI Facts, Figures and National Registries
  3:00 a" 4:05 pm (Main Arena)
  Featuring new clinical data from TAVI registries in Belgium, France, Germany, Italy and the U.K. (all include the CoreValve system; the Italian registry includes on the CoreValve system)
• Hotline 4 a" Late Breaking Trials
  4:05 a" 5:35 pm (Main Arena)
  Featuring one-year results of the RESOLUTE All-Comers study, the first randomized, head-to-head comparison of the Resolute zotarolimus-eluting and the Xience V everolimus-eluting coronary stents (the first presentation of the primary clinical and secondary angiographic outcomes)

Wednesday, May 26 (Day 2)

• TAVI: mid- and long-term clinical outcomes
  12:00 noon a" 1:30 pm (Room 243)
  Starts with aStable durability and effectiveness at 2 years with the CoreValve transcatheter aortic valvea; also includes aMedium-term results of transcatheter aortic valve implantation with the CoreValve: the Italian Registrya (one of the largest country-specific registries of CoreValve patients)
• Emerging technologies and therapies in endovascular interventions a"
  Drug-eluting balloon in peripheral vascular interventions
  1:30 a" 3:00 pm (Vend'me)
  Includes aThe value of drug-eluting balloons for below-the-knee interventionsa(a presentation of the Leipzig 100-patient single-center clinical data on the IN.PACT Amphirion drug-eluting balloon)
• Cardiovascular Innovation Pipeline @ EuroPCR
  4:30 a" 6:30 pm (Room 243)
  Spans nine recent technological advances, including aContinuous sinusoid technology a" the future of Medtronica™s stent pipelinea (based on the Integrity^® bare-metal stent)

Thursday, May 27 (Day 3)

• TAVI: new insights from imaging
  8:00 a" 9:00 am (Room 253)
  Includes aSerial echocardiographic evaluation of the CoreValve aortic bioprosthesis: the Italian Registry,a an examination of left ventricular remodeling following CoreValve implantation
• What do Resolute All Comers data tell us about the treatment of complex disease and complex patients
  12:00 noon a" 1:30 pm (Theatre Havane)
  (supported with an unrestricted educational grant from Medtronic)
• From drug-eluting stent to drug-eluting balloon:
  the role of drug-eluting balloons in percutaneous coronary intervention
  4:30 a" 6:00 pm (Theatre Havane)
  Features the first presentation of the Homburg/Saar 23-patient single-center clinical data on the IN.PACT Falcon drug-eluting balloon for coronary in-stent restenosis; also includes additional presentations on the use of the IN.PACT line of drug-eluting balloons in coronary arteries, including small vessels, and peripheral applications (supported with an unrestricted educational grant from Medtronic)

In the United States, the Resolute drug-eluting stent is limited by U.S. federal law to investigational use only. The Integrity bare-metal stent, the CoreValve transcatheter aortic valve, and the IN.PACT Amphirion and Falcon drug-eluting balloons are not available for sale or investigation in the United States. All of these devices have received the CE (Conformit© Europ©enne) mark, making them widely available outside the United States and Japan.

The CardioVascular business at Medtronic is committed to advancing the treatment of coronary, peripheral, aortic and structural heart disease through collaboration with leading clinicians, researchers and scientists worldwide.

About Medtronic

Medtronic, Inc. ([ www.medtronic.com ]), headquartered in Minneapolis, is the global leader in medical technology a" alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronica™s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.